HIGH RISK MYELODYSPLASTIC SYNDROME
Clinical trials for HIGH RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new HIGH RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for HIGH RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tame tough blood cancers
Disease control Recruiting nowThis study tests a combination of two drugs—CPX-351 (a liposomal form of standard chemotherapy) and quizartinib—in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the best dose and see if the combo can control the cancer. …
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 06:32 UTC
-
Promising drug cocktail targets tough blood cancer
Disease control Recruiting nowThis study tests adding the drug venetoclax to standard chemotherapy for people with acute myeloid leukemia (AML), either newly diagnosed or that has returned or not responded to treatment. About 116 adults will take part to find the best dose and see how well the combination wor…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 06:15 UTC
-
Heart shield: new study tests drug to prevent chemo side effects
Disease control Recruiting nowThis study tests whether a drug called dexrazoxane can protect the heart from damage caused by chemotherapy in people with certain blood cancers, like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). About 100 participants will receive dexrazoxane alongs…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for tough blood cancers: CBX-250 trial opens
Disease control Recruiting nowThis early-stage study tests a new drug called CBX-250 in about 72 people with certain blood cancers (like acute myeloid leukemia) that have returned or not improved with standard therapy. The main goals are to check the drug's safety and find the best dose. Participants receive …
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New drug cocktail shows promise for tough blood cancers
Disease control Recruiting nowThis study tests a combination of four drugs (cladribine, idarubicin, cytarabine, and quizartinib) in people with acute myeloid leukemia or high-risk myelodysplastic syndrome that is either newly diagnosed or has returned/not responded to treatment. The goal is to see if this mix…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New drug combo targets hard-to-treat leukemia in early trial
Disease control Recruiting nowThis study tests a mix of chemotherapy drugs for people newly diagnosed with a specific type of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The goal is to see how well the treatment kills cancer cells and what side effects it causes. About 270 adults will …
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:52 UTC
-
Metal detox may boost chemo for blood cancer patients
Symptom relief Recruiting nowThis early-phase study tests whether two metal-removing drugs (edetate calcium disodium and succimer) are safe and can help control acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) when given alongside chemotherapy. About 58 adults with these blood cancers will rece…
Matched conditions: HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 17, 2026 06:20 UTC